Extracorporeal liver devices have gained attention as a complementary approach to liver transplantation in patients with acute on chronic liver failure.
Molecular Adsorbent Recycling System (MARS) is a hemodiafiltration against albumin, which is able to remove low molecular weight toxins.
In this study, the researchers from Italy validated the use of MARS in patients presenting with acute on chronic liver failure with severe cholestasis.
|MARS improves neurological status and hemodynamic stability.|
The team enrolled 7 patients with acute on chronic liver failure, who presented with bilirubin >25 mg/dl and hepatorenal syndrome, and/or hepatic encephalopathy grade >II.
They evaluated a number of parameters both before and after each MARS treatment. These included liver biochemistry, coagulation, blood cell count, electrolytes, ammonia, lactate, blood urea nitrogen, creatinine, bile acids, Fischer ratio, and encephalopathy grade.
Dr Cristiana Di Campli’s team concluded, “MARS can represent a safe therapeutic choice to achieve a quick improvement of neurological status, a hemodynamic stability, and a better clinical outcome”.
“In particular, our encouraging results suggest that also, patients with severe cholestasis may represent in the future a good indication for MARS treatment”.